Aura Biosciences, Inc. (AURA)
NASDAQ: AURA · IEX Real-Time Price · USD
8.67
-0.15 (-1.70%)
At close: Jul 19, 2024, 4:00 PM
8.80
+0.13 (1.50%)
Pre-market: Jul 22, 2024, 8:36 AM EDT
Aura Biosciences Employees
As of December 31, 2023, Aura Biosciences had 89 total employees, including 88 full-time and 1 part-time employees. The number of employees increased by 17 or 23.61% compared to the previous year.
Employees
89
Change (1Y)
17
Growth (1Y)
23.61%
Revenue / Employee
n/a
Profits / Employee
-$883,685
Market Cap
429.54M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89 | 17 | 23.61% |
Dec 31, 2022 | 72 | 20 | 38.46% |
Dec 31, 2021 | 52 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Health Catalyst | 1,300 |
Editas Medicine | 265 |
Nano-X Imaging | 164 |
Nkarta | 150 |
C4 Therapeutics | 145 |
Korro Bio | 102 |
Kyverna Therapeutics | 96 |
Ocugen | 65 |
AURA News
- 7 weeks ago - Aura Biosciences to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024 - GlobeNewsWire
- 2 months ago - Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights - Business Wire
- 8 months ago - Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma - Business Wire
- 9 months ago - Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights - Business Wire
- 9 months ago - Aura Biosciences Announces Pricing of Public Offering of Common Stock - Business Wire